The story of BioNTech has shifted from pandemic winner to pipeline builder, and the transition is proving uncomfortable. Investors have watched the stock slide nearly 22% over the past year, with shares recently trading at €74.70 — just 8.3% above the 52-week low of €68.35. A modest 0.88% daily gain does little to mask the broader picture: the market is demanding commercial results, not scientific accolades.
The company’s response has been structural. At the annual general meeting in mid-May, shareholders approved an expansion of the supervisory board from six to eight members. New appointees bring expertise in clinical development, sales, and product launches — a clear signal that BioNTech is retooling its governance for the next phase of its oncology offensive. The board is no longer a scientific advisory body; it is being shaped to oversee the transition from discovery to market.
That transition remains unproven in revenue terms. BioNTech posted first-quarter 2026 revenue of €118.1 million, down 35% from a year earlier, while the net loss widened 28% to €531.9 million. Management expects full-year revenue between €2.0 billion and €2.3 billion, but planned R&D spending of €2.2 billion to €2.5 billion means the company will spend more on development than it generates in sales. The arithmetic is blunt: the oncology pipeline is being funded by the shrinking Covid franchise, and investors are being asked to wait for a payoff that has no set date.
The clinical evidence for that payoff is mounting. At the ASCO conference on May 30, BioNTech and Bristol Myers Squibb presented interim data from the Phase 2 ROSETTA Lung-02 trial of Pumitamig in first-line advanced non-small cell lung cancer. The drug, combined with chemotherapy, delivered high confirmed objective response rates across all subtypes and PD-L1 expression levels, a 100% disease control rate, and a manageable safety profile. Separately, the PRESERVE-004 study of Gotistobart plus pembrolizumab in platinum-resistant ovarian cancer showed durable anti-tumor effects and clinically relevant survival data as a chemotherapy-free option.
Should investors sell immediately? Or is it worth buying BioNTech?
These results underscore the breadth of BioNTech’s pipeline: more than 25 Phase 2 and Phase 3 studies are underway, including 13 registration trials. The company plans to launch six more Phase 3 studies in 2026 and expects seven late-stage data packages. The FDA has granted Fast Track designations for its FixVac mRNA vaccine programs, including BNT113 for HPV16-positive head and neck cancer and BNT111 for advanced melanoma. Yet none of this has produced a single euro of oncology revenue.
The market’s skepticism is reflected in technical indicators. The stock sits 13% below its 200-day moving average of €85.77, and the 50-day average of €81.02 now acts as resistance rather than support. The relative strength index stands at 34.6, flirting with oversold territory. Annualized volatility of nearly 29% reminds investors this is no steady value play. After the ASCO data, the share price barely moved.
That disconnect is not irrational. It reflects a market that has learned to distinguish between pipeline promise and commercial delivery. BioNTech is also reorganizing its manufacturing footprint to cut overcapacity, directing savings into the oncology commercialization push. But cost discipline, while necessary, is not a substitute for approved products and reimbursement deals. A further risk looms at home: proposed cuts to the German healthcare system could constrain pricing power just as BioNTech’s first oncology products approach market entry.
Analysts remain bullish on the potential. The average price target of €106.37 implies upside of nearly 44%. But that gap between target and current price can be read two ways: either the stock is deeply undervalued, or the market has decided to wait for tangible results before paying up. For now, BioNTech must generate events — regulatory filings, pivotal data readouts, and ultimately approvals — that close the chasm between clinical progress and commercial confidence. The second-quarter report, due in a few weeks, will be the next test. Until then, the stock remains trapped between technical support and a wall of skepticism that strong science alone has not yet breached.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from June 9 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 9.
BioNTech: Buy or sell? Read more here...
